Synthesis, characterization, and in silico studies of 1,8-naphthyridine derivatives as potential anti-Parkinson's agents. 2023

Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.

1,8-Naphthyridine scaffold is a nitrogen-containing heterocyclic compound known for its versatile biological activities. The structure-activity relationship (SAR) has shown that modification at the 3rd position of the nucleus with various secondary amines enhances the binding efficiency and potency towards the Adenosine receptor (A2A type). In this paper, we have reported some newly synthesized derivatives of 1,8- Naphthyridine, and the prepared compounds were assessed for their potential to constrain A2A receptors through molecular docking. Based on the SAR studies, modifications were done at the 3rd position of the nucleus by incorporating secondary amines. The synthesized compounds were characterized by FT-IR, 1H and 13C NMR. All the synthesized compounds 10a-f and 13a-e showed good binding efficiency towards the A2A receptors and might act as an A2A receptor antagonist, as predicted by in-silico studies. 1-Ethyl-7-methyl-3-(pyrrolidine-1-carbonyl)-1,8-naphthyridine-4(1H)-one (10c) in first series showed the highest docking score of -8.407 and binding energy (MMGBSA dG bind) of -56.60 kcal/mol and N-(4-2-diethylaminoethoxyphenyl)-1-ethyl-7-methyl-4-oxo-1, 4, 4a, 8a- tetrahydro-1,8-naphthyridine-3-carboxamide (13b) showed the highest docking score of -8.562 and free binding energy (MMGBSA dG bind) score of -64.13 kcal/mol which was comparable to the bound ligand. MD simulations study also suggested that compounds 10c and 13b would form stable complex human A2A receptor. These findings need to be validated by further in vitro assays.Communicated by Ramaswamy H. Sarma.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017550 Spectroscopy, Fourier Transform Infrared A spectroscopic technique in which a range of wavelengths is presented simultaneously with an interferometer and the spectrum is mathematically derived from the pattern thus obtained. FTIR,Fourier Transform Infrared Spectroscopy,Spectroscopy, Infrared, Fourier Transform
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
November 1986, Il Farmaco; edizione scientifica,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
December 1984, Chemical & pharmaceutical bulletin,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
April 2014, Organic & biomolecular chemistry,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
June 2002, Biological & pharmaceutical bulletin,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
January 2024, RSC medicinal chemistry,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
September 1962, Journal of medicinal and pharmaceutical chemistry,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
September 2020, Journal of biomolecular structure & dynamics,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
January 1980, Chemical & pharmaceutical bulletin,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
March 1980, Chemical & pharmaceutical bulletin,
Madhwi Ojha, and Avinash Kumar, and Chakrawarti Prasun, and Maya S Nair, and Saurabh Chaturvedi, and Sarvesh Kumar Paliwal, and Sumitra Nain
July 1946, Journal of the American Chemical Society,
Copied contents to your clipboard!